p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α–mediated down-regulation of CXCL12Kensuke Kojima, Michael Andreeff, Elizabeth J. Shpall et al.|Blood|2011Cited by 105
Phase 1 study of combinatorial sorafenib, <scp>G‐CSF</scp>, and plerixafor treatment in relapsed/refractory, <scp>FLT3‐ITD</scp>‐mutated acute myelogenous leukemia patientsGautam Borthakur, Michael Andreeff, Zhihong Zeng et al.|American Journal of Hematology|2020Cited by 38
Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating DrugsJo Ishizawa, Michael Andreeff, Marina Konopleva et al.|PLoS ONE|2015Cited by 24